Results 151 to 160 of about 663,812 (384)
Updates on the use of non-invasive brain stimulation in physical and rehabilitation medicine
John A. Williams +2 more
openalex +1 more source
Financial Distress and Its Determinants in Rheumatoid Arthritis
Objective To quantify the degree of financial distress and identify its determinants in adults with rheumatoid arthritis (RA) given the frequent prolonged use of expensive disease‐modifying therapies. Methods We identified adults enrolled in the FORWARD databank with either RA or noninflammatory musculoskeletal disease (NIMSKD) completing the ...
Amber Brown Keebler +5 more
wiley +1 more source
Editorial: Biomechanical performance and relevant mechanism of physical medicine and rehabilitation for neuromusculoskeletal disorders. [PDF]
Song Q +5 more
europepmc +1 more source
Physical and rehabilitation medicine in the XXI century: challenges and opportunities
Filipa Faria
openalex +2 more sources
Objective We aimed to test the efficacy of personalized treatment of older Veterans with chronic low back pain (CLBP) delivered by Aging Back Clinics (ABC) as compared with usual care (UC). Methods Two hundred ninety‐nine Veterans age 65‐89 with CLBP from 3 VA medical centers underwent baseline testing, randomization to ABC or UC and 12 months follow ...
Debra K. Weiner +9 more
wiley +1 more source
Christoph Gutenbrunner, Boya Nugraha
doaj +1 more source
Objective Axial spondyloarthritis (axSpA) is often associated with persistent pain despite effective anti‐inflammatory treatment. Digital health applications (DHAs) provide innovative approaches to address multidimensional aspects of persistent pain through psychological and behavioral strategies. The aim of this study was to assess the impact of a DHA
David Kiefer +7 more
wiley +1 more source
Abena Tannor
doaj +1 more source
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti +19 more
wiley +1 more source
Nicolas Christodoulou
doaj +1 more source

